Latest AIDS Clinical Trials Group Stories
ANAC appoints Carole Treston, RN, MPH as first Chief Nursing Officer. Akron, Ohio (PRWEB) December 05, 2013 The
A new multi-site study reveals patients with drug-resistant HIV can safely achieve viral suppression – the primary goal of HIV therapy – without incorporating the traditional class of HIV medications into their treatment regimen.
In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.
A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning "the whole treatment world on its head," according to Dartmouth pediatrician Paul Palumbo.
Findings from a study, which appear in the Oct. 14, 2010 New England Journal of Medicine, helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV-infected women who receive a single dose of the antiretroviral drug nevirapine to prevent HIV transmission to their babies.
Two studies appearing in the October 14, 2010 New England Journal of Medicine and funded by the National Institutes of Health helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV infection in certain women and children.
BRISBANE, Calif., Jan. 11 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today provided an update on its development program for protease inhibitor RG7227 (formerly referred to as ITMN-191) for the treatment of patients chronically infected with the hepatitis C virus (HCV).
Prevention versus treatment? Cost versus efficacy? So go two of the dilemmas looming over Dartmouth's Paul E. Palumbo, M.D., and his fellow researchers in the race to fight HIV and other infectious diseases in the developing world â€” especially among women and their young children.
MEXICO CITY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced that a retrospective analysis of six clinical trials found that anti-HIV regimens containing EPZICOM (abacavir + lamivudine) were effective in treatment-naive patients regardless of baseline viral loads.
- An interdisciplinary study of social injustice.